AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01107639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: During the adjuvant phase, all infusions, given every two weeks, will be at a dose of 500mg/m².
Study NCT01107639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: During the neoadjuvant phase, the first infusion of cetuximab should be at a dose of 400 mg/m² administered over a period of 2 hours and all subsequent infusions, given weekly, should be of 250 mg/m² over a period of 1 hour, unless any infusion related reaction was observed at a previous infusion. (The maximum infusion rate is 10 mg/min, corresponding to 2 mL/min ready-to-use solution.
Study NCT02769078 — intervention group
Intervention type: DRUG
Intervention: warfarin
Study NCT04608019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Antibiotics
Description: increase airway clearance/start oral antibiotics right away
Study NCT04608019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Treatment
Description: increase airway clearance and start oral antibiotics later if symptoms get worse or do not get better
Study NCT00003873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV or orally
Study NCT00003873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eniluracil
Description: Given orally
Study NCT00552071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR 30 MG Injection
Description: Stable dose of 30 mg octreotide LAR, or a dose determined by historical dosing, delivered every 28 days for 3 months.
Study NCT00552071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR 30 MG Injection
Description: Stable dose of 30 mg octreotide LAR, or a dose determined by historical dosing, delivered every 28 days for 3 months.
Study NCT01900067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BARRIER® EasyWarm Active Self-Warming Blanket
Study NCT04937634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: The subject receives conditioning regimen including melphalan as a part of hematopoietic stem cell transplantation. Dosage of melphalan is 50mg/m\^2/day. Infuse Melphalan over 30 minutes.
Study NCT01096108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard contest (1 month)
Description: Smoking abstinence, 1 prize award (month 1)
Study NCT01096108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational and Problem-Solving
Description: Counseling phone calls
Study NCT01096108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Contests
Description: Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
Study NCT00638300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: large pore (FX80) compared to small pore dialyzer (F8HPS)
Description: Effect of pore size
Study NCT00638300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L
Description: Effect of dialysate bicarbonate concentration
Study NCT00638300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L
Description: Effect of dialysate calcium concentration
Study NCT00330369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan
Description: Darusentan administered orally once daily
Study NCT00330369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan Placebo
Description: Placebo to match darusentan administered orally once daily
Study NCT00330369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Darusentan Placebo
Description: Placebo to match darusentan administered orally once daily
Study NCT04276194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Proton Therapy
Description: Undergo intensity modulated proton therapy
Study NCT01102231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
Study NCT01102231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERBITUX
Description: The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
Study NCT01102231 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 66 Gy (2 Gy by fraction, 5 fractions by week)
Study NCT03303287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School health education
Description: School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
Study NCT01245764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
Study NCT01245764 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02679196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KA2237
Description: PI3 Kinase p110β/δ inhibitor
Study NCT04717778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comparison of salivary pH after consuming milk of origin vegetable vs cow's milk
Description: They were given 5 types of milk, each one was measured on different days (Monday cow's milk, Tuesday coconut milk, Wednesday almond milk, Thursday soy milk, Friday rice milk).
Study NCT01095796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild
Description: Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
Study NCT04276194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03170427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sensory level
Description: Sensory levels are checked using touch with alcohol puffs
Study NCT03170427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sensory level
Description: Sensory levels are checked using touch with alcohol puffs
Study NCT00725751 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pegylated interferon alfa-2b (PegIFN-2b)
Description: PegIFN-2b administered according to European labeling.
Study NCT00725751 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin administered according to European labeling.
Study NCT02914093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMT
Description: Inspiratory muscle training for 6 weeks 2x30 breaths daily as a home based program
Study NCT01093664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE AD02
Description: s.c. injection
Study NCT01660399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boanmycin
Description: Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
Study NCT01660399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2, intravenous infusion, day 1.
Study NCT01660399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2, intravenous infusion, day 1.
Study NCT03679052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Each patient received 30 mg mirtazapine tablet and a placebo tablet for clonidine orally with sips of water 2 h preoperatively.
Study NCT03679052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Each patient received 150 µg clonidine tablet and a placebo tablet for mirtazapine orally with sips of water 2 h preoperatively.
Study NCT03679052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
Study NCT01484613 — intervention group
Intervention type: DEVICE
Intervention: quadripolar LV lead (Quartet)
Description: All participants will receive CRT-D system with a quadripolar lead. This lead offers 10 LV lead vectors to choose from
Study NCT00537927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic correction of hernia with mesh
Description: Correction of hernia with mesh and fixation of mesh using one of the arms.
Study NCT02733315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Conversation Map Program
Description: The experiment group received seven DCMP-based group education sessions for seven consecutive weeks in addition to routine health education at a private room in the outpatient unit. One registered nurse who received DCMP facilitator training, from the Taiwanese Association of Diabetic Educators, served as the class facilitator. DCMP sessions were conducted using seven colored maps covering different topics, including walk with diabetes, what is diabetes?, a healthy diet and exercise, walk with insulin, diabetes complications and related risk factors, foot care for diabetes patients, and a type 1 diabetes patient in the home. Each map, a laminated 3-by-5-foot table-top visual with colorful drawings as metaphors of situations familiar to DM patients, was placed on a table with participants gathered around it. This procedure served to create mutual imagery to be shared with participants.
Study NCT03688282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable vibration belt
Description: The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips.
Study NCT03688282 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham, wearing belt
Description: The device is worn, for a specified time. It will not be turned on during this period. It is only sham.
Study NCT02583386 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Free From Falls fall prevention program
Description: Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.
Study NCT02583386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Fall Detector
Description: 30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
Study NCT02583386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Fall Detector
Description: 30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
Study NCT04236570 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thermode(hot plate) and cold water bath
Description: Standardized protocol will consisted of stimulus test (TS) generated by thermode and conditioning stimulus (CS) using cold water bath.
Study NCT04236570 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TENS(transcutaneous electrical nerve stimulation)
Description: TENS protocol will consisted of test stimulus (TS) and conditioning stimulus (CS) both generated by TENS
Study NCT04214925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Home exercises will include warm-up and cool-down exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles.
Study NCT04214925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tai Chi
Description: Home exercises will include warm-up and cool-down exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles.
Study NCT01095796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla
Description: Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime
Study NCT01095796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stribild Placebo
Description: Placebo to match Stribild STR administered orally once daily
Study NCT01095796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla Placebo
Description: Placebo to match Atripla tablet administered orally once daily prior to bedtime
Study NCT02752230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Roux en Y gastric bypass
Description: Laparoscopic Roux en Y gastric bypass
Study NCT02294422 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PBP
Description: the pilot balloon is continuously palpated o felt for adequate pressure as its being inflated.
Study NCT02294422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOR
Study NCT02294422 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aneroid manometer
Description: The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.
Study NCT02294422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aneroid manometer
Description: The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.
Study NCT02278081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lansoprazole
Description: the lansoprazole will be taken orally.
Study NCT02278081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the lansoprazole placebo will be taken orally.
Study NCT04021459 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood samples
Description: 3 samples: One before surgery on the arm vein (peripheral)~Two during the surgery, on two different venipuncture site :~* One on the arm vein (peripheral)~* One on ovarian vein (close to the tumor) All samples will be tested by the CellSearch method.
Study NCT04572581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor Breast Milk
Description: Donor breast milk will be given to the newborn if supplementation is required
Study NCT03015025 — intervention group
Intervention type: GENETIC
Intervention: Acenocoumarol
Description: A blood sample was collected for CYP2C9, VKORC1, CYP4F2, APOE and 2 variants of POR genotypes.
Study NCT03820726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Bid
Study NCT00345540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV-002
Description: 60 mg / mL / day / 20-23 Days
Study NCT00345540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 following IV bolus administration of NOV-002
Study NCT01011218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBT-I
Description: Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone
Study NCT01011218 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: BBT-I
Description: Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone
Study NCT01011218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control behavioral intervention is a sleep hygiene handout completed by participant.
Study NCT01011218 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control behavioral intervention is a sleep hygiene handout completed by participant.
Study NCT01011218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.
Study NCT02233907 — intervention group
Intervention type: DRUG
Intervention: Ventilat® - metered dose inhaler
Study NCT01539811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical incision and drainage of diabetic foot infection
Description: Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot
Study NCT01539811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short course antibiotics
Description: Short course (\<2 weeks) of antibiotics will be prescribed
Study NCT01539811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long course antibiotics
Description: Long course (>2 weeks) of antibiotics will be prescribed
Study NCT03424317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sodium intake reduction
Description: Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively
Study NCT03424317 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively
Study NCT03424317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively
Study NCT03010722 — intervention group
Intervention type: DRUG
Intervention: Regorafenib
Description: Patients meeting all of the inclusion criteria and none of the exclusion criteria will receive regorafenib 160 mg orally (po) od for 3 weeks of every 4-week cycle. Each cycle will comprise 3 weeks of treatment followed by 1 week without treatment, hereafter described as 3 weeks on/1 week off. Each 160-mg dose will include four regorafenib 40-mg tablets.
Study NCT03384108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-13C-Glutamine
Description: Intravenous infusion of 5-13C-Glutamine
Study NCT03384108 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bone marrow aspiration
Description: Bone marrow aspiration of bone marrow aspirate
Study NCT03384108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Bone marrow aspiration of bone marrow aspirate
Study NCT02644837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of Ambu AuraGain laryngeal mask airway and Igel
Description: Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction
Study NCT02644837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fibreoptic assessment with Ambu A-scope
Description: Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised
Study NCT02644837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ability to insert nasogastric tube
Description: Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance
Study NCT02644837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of OLP
Description: Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute
Study NCT02644837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ability to perform positive pressure ventilation
Description: The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed
Study NCT02644837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of ease of insertion
Description: Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device
Study NCT02644837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Record number of manipulations
Description: The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
Study NCT03581175 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Study NCT03581175 — intervention group
Intervention type: DRUG
Intervention: Bowel cleansing regimen
Study NCT03186768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soap on a rope hall pass intervention
Description: School health and nutrition coordinators will be trained on how to make and utilize the soap on a rope hall pass to improve hand washing behavior in schools.
Study NCT01381367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPSV23 pneumococcal vaccine (Pneumovax®)
Description: The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.
Study NCT01381367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline, 0.5ml given subcutaneously
Study NCT04203589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Explorer Baby Early Intervention Program
Description: Centered based intervention, once or twice a month, 6 months follow up
Study NCT04203589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy
Description: Centered based intervention, once or twice a month, 6 months follow up
Study NCT01405183 — intervention group
Intervention type: OTHER
Intervention: Hepatitis C testing
Description: Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
Study NCT01322256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone scintigraphy
Description: Bone scintigraphy of the affected area
Study NCT01322256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukoscan
Description: Scintigraphy with labeled neutrophils